'The fundamentals are really strong': Why investors are staying loyal to European biotech in 2023

While the biotech bull market hasn’t charged back in 2023 as many had hoped, European-focused venture capital firms don’t seem to have had problems bringing in money.

In fact, both Forbion and BioGeneration Ventures announced their largest biopharma funds to date earlier this year. Meanwhile, Germany’s High-Tech Gründerfonds, which invests across life sciences, digital tech and high tech, also saw its largest raise at almost half a billion euros.